Background-Neutrophil gelatinase-associated lipocalin (NGAL) is an early marker of acute kidney injury (AKI). Methods and Results-Urine NGAL and serum NGAL (sNGAL) were assessed at 2, 6, 24, and 48 hours after contrast media (CM) exposure in 458 high-risk patients (development set). Optimal thresholds in predicting contrast-induced AKI (serum creatinine [sCr] increase ≥0.3 mg/dL at 48 hours after CM administration) were identified. Major adverse events (MAE; death, dialysis, nonfatal myocardial infarction, sustained kidney injury, and myocardial revascularization) at 1 year were assessed. In the development set, optimal thresholds for contrast-induced AKI occurred at 6 hours for both urine NGAL (≥20 ng/mL; 97% negative predictive value and 27% positive predictive value) and sNGAL (≥179 ng/mL; 93% negative predictive value and 20% positive predictive value). Furthermore, sNGAL ≥179 ng/mL at 6 hours was an independent predictor of 1-year MAE. 1-year MAE occurred in 27/198 patients (13.5%) with sNGAL <179 ng/mL and sCr <0.3 mg/dL, in 57/193 (29.5%) patients with only sNGAL ≥179 ng/mL, and in 37/67 (55%) patients with sCr ≥0.3 mg/dL. In additional 253 patients (validation set), no patient with urine NGAL <20 ng/mL or sNGAL <179 ng/mL at 6 hours developed contrast-induced AKI. Furthermore, 6/68 (9%) patients with sNGAL <179 ng/mL and sCr increase <0.3 mg/dL had 1-year MAE versus 17/57 (30%) patients with sNGAL ≥179 ng/mL and sCr increase <0.3 mg/dL and 8/16 (50%) patients with sCr increase ≥0.3 mg/dL. Conclusions-Urine NGAL <20 ng/mL and sNGAL <179 ng/mL at 6 hours are reliable markers for ruling out contrastinduced AKI. sNGAL ≥179 ng/mL at 6 hours predicts 1-year MAE. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01098032. (Circ Cardiovasc Interv. 2015;8:e002673.
I odinated contrast media (CM) administration during coronary and peripheral procedures may cause acute kidney injury (AKI). 1 The current recommendations suggest (1) serum creatinine (sCr) as the gold standard and (2) an extended observation (≥24 hours) for patients undergoing coronary procedures with significant renal dysfunction even in case of otherwise uncomplicated clinical course. 2 Several biomarkers of kidney injury have shown diagnostic and prognostic value. 3 Neutrophil gelatinase-associated lipocalin (NGAL), a ubiquitous 25-kDa protein covalently bound to gelatinase from human neutrophils, is a marker of kidney tubular injury. 4, 5 Serum NGAL (sNGAL) and urine NGAL (uNGAL) predict AKI in different clinical settings, [6] [7] [8] [9] including contrast-induced AKI (CI-AKI). 10, 11 Overall, NGAL is an useful tool for early diagnosis (within a few hours) and prognosis (prediction of renal replacement therapy and inhospital mortality) of AKI. 9, 12, 13 However, there is only limited data on (1) the optimal timing and site (urine/serum) for assessment, (2) the cut-off value, (3) comparison with cystatin C, 14 and (4) the clinical and prognostic significance in the setting of CI-AKI.
Objectives of the present study are (1) the assessment of the diagnostic usefulness of NGAL in the setting of CI-AKI in patients with moderate-to-severe chronic kidney disease undergoing coronary or peripheral angiography or angioplasty and (2) the prognostic significance of high NGAL values, used as an index of kidney damage, irrespective to the presence or absence of changes in kidney function, defined on the basis of sCr changes.
Methods

Patient Population
Development Set
From January 2009 to October 2012, 458 patients scheduled for coronary or peripheral angiography or angioplasty with an estimated glomerular filtration rate (eGFR) ≤30 mL/min per 1.73 m 2 or Mehran risk score ≥11 were included in this study. Part of these patients (n=280) had been enrolled in the Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL) II (registration on http://www.clinicaltrials.gov; ID: NCT01098032). 15 CI-AKI prophylaxis strategies for the 280 patients enrolled in the REMEDIAL II were (1) hydration with sodium bicarbonate solution (154 mEq/L) 16 plus high dose of N-acetylcysteine or (2) hydration with normal saline plus Nacetylcysteine controlled by the RenalGuard system (PLC Medical Systems, Inc, Franklin, MA). 15 All the other patients (including those in the validation set) were treated with the RenalGuard system as a result of the positive results of the REMEDIAL II.
Validation Set
From November 2012 to December 2014, 253 patients scheduled for coronary or peripheral angiography or angioplasty with an eGFR ≤30 mL/min per 1.73 m 2 or Mehran risk score ≥11 were analyzed.
The eGFR was calculated with the Modification of Diet in Renal Disease 17 and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. 18 The risk score for predicting CI-AKI was defined according to Mehran et al. 19 Iodixanol (Visipaque 320 mg I/mL; GE), a nonionic, iso-osmolar CM, was used in all patients. CM volume >3× eGFR was considered suggestive of increased risk of CI-AKI. 20 The study was accepted by the ethical committee, and an informed consent was obtained from all patients.
WHAT IS KNOWN
• Serum creatinine is the gold standard for the diagnosis of contrast-induced acute kidney injury. However, serum creatinine requires 24 to 48 hours to increase, despite immediate impairment in glomerular filtration rate by contrast media-induced injury.
• Neutrophil gelatinase-associated lipocalin has emerged as an early biomarker of contrast-induced acute kidney injury.
WHAT THE STUDY ADDS
• Neutrophil gelatinase-associated lipocalin at 6 hours after contrast media exposure is a reliable marker for ruling out contrast-induced acute kidney injury because of its excellent negative predictive value.
• High neutrophil gelatinase-associated lipocalin at 6 hour after contrast media exposure is associated with a significant serum creatinine increase in only 20% of cases, but is an independent predictor of 1-year major adverse events. 
Biomarkers of Kidney Function and Injury
Blood urea nitrogen, sCr, and cystatin C were measured the day before and 2, 6, 12, 24, and 48 hours after administration of the CM; additional measurements were performed on deterioration of baseline renal function. uNGAL and sNGAL were measured the day before and 2, 6, 24, and 48 hours after CM administration. Urine was collected and stored at −80°C until analysis with the automated immunoassay ARCHITECT platform (Abbott Diagnostic, Abbott Park, IL). Intra-and interassay variabilities were 3.5% and 10%, respectively. Urine creatinine (uCr), measured by quantitative colorimetric microplate assay kit, was used to normalize uNGAL for changes in urine concentration (uNGAL/uCr or normalized uNGAL). Blood samples were centrifuged at 4000 rpm (1400g) for 20 minutes, and the serum harvested and stored in aliquots at −80°C until analysis with the Human NGAL Rapid ELISA Kit (BioPorto Diagnostics A/S, Gentofte, Demnark). Intra-and interassay variabilities were 3.4% and 7%, respectively. All NGAL measurements were performed in a central core laboratory (Federico II University) by independent and blinded operators.
Events Definition
CI-AKI was defined as an increase in the sCr concentration ≥0.3 mg/dL from the baseline at 48 hours after CM administration or the need for dialysis. 21 Major adverse events (MAE) at 1 year included all-cause death, dialysis, nonfatal myocardial infarction, myocardial revascularization, and sustained kidney injury (ie, a persistent ≥25% eGFR reduction compared with baseline at the last follow-up available value). The length of in-hospital stay (LOS) was calculated as the sum of the number of days since admission until discharge from the hospital. LOS was collected to assess (1) its difference in patients with versus those without CI-AKI and (2) the impact of the current recommendation for the diagnosis of CI-AKI in patients who did not developed CI-AKI. 2 One-year follow-up was available in all patients in the development set and in all the 141 of the 253 (56%) patients in the validation set enrolled within December 2014. All events were adjudicated by a Clinical Events Committee, who was blinded to both sCr and NGAL levels.
Statistical Analysis
Continuous variables are given as mean±SD or median (interquartile range) as appropriate. Normality assumption was verified graphically (ie, quantile-quantile plot) and was confirmed using the Shapiro-Wilk test. Categorical variables are expressed in percentages. Comparisons between groups were performed by Student's t test or χ 2 test. Spearman correlation test was used to evaluate the relation between different biomarkers. To test the predictive value of absolute and normalized uNGAL and the value of sNGAL for CI-AKI, we used mixed model for repeated measures after transforming absolute uNGAL, uCr, and sNGAL levels into natural logarithm, and so overcoming the problem of the non-normal distribution. In this model, the NGAL values and time period interaction were considered as fixed effects and patients as a random effect. Mann-Whitney U test was performed to assess potential time-related changes in uNGAL, sN-GAL, and uNGAL/uCr ratio in relation to the occurrence of CI-AKI or MAE. Receiver operating characteristic curves were generated, and the area under the curve (AUC) was calculated to evaluate the diagnostic sensitivity and specificity of the biomarkers at different time points (baseline, 2, 6, and 24 hours) for CI-AKI and 1-year MAE. Optimal cut-offs were identified by the Youden index. 22 Multiple logistic regression analysis was performed to determine whether the biomarkers were independent predictors of CI-AKI, adjusting for several clinical variables, selected according to data in the literature and significance (P<0.1) at univariate analysis. To overcome the risk of collinearity between NGAL and eGFR, the regression model was run with and without eGFR in the model. To assess the independent predictive power of both functional (sCr) and injury (NGAL) biomarkers, 3 groups were defined and analyzed: (1) group without sCr increase ≥0.3 mg/dL or sNGAL ≥179 ng/mL (group without kidney damage or functional change); (2) group with sNGAL ≥179 ng/mL alone (group with kidney damage); and (3) group with sCr increase ≥0.3 mg/dL, irrespective to the sNGAL values (group with functional change). The Kaplan-Maier method was used to calculate event-free survival, and comparison between groups was performed by using the log-rank statistic. Cox proportional hazards model was performed to provide hazard ratios with 95% confidence intervals and adjustment for previously selected risk factors, as reported for the multiple logistic regression analysis. To correct for multiple testing, 1000 bootstrap iterations were computed. For all tests, P<0.05 was considered statistically significant. Data were analyzed with STATA software (ver-sion11/SE, College Station, TX).
Results
CI-AKI and NGAL
Baseline features of the patients in the development set, stratified for CI-AKI, are reported in Table 1 . The characteristics of the patients enrolled in the REMEDIAL II (n=280) versus those in the Non-REMEDIAL II (n=178) are reported in the Table I in the Data Supplement. Patients who experienced CI-AKI had more severe chronic kidney disease, had a higher rate of peripheral vascular disease, received a greater volume of CM, and were less often treated by the RenalGuard system. LOS was longer in patients who developed CI-AKI (10±6 versus 6±4 days; P<0.001). In patients who did not developed CI-AKI, LOS stay was prolonged for ≈1 day only for ruling out the occurrence of CI-AKI. Indeed, in these patients, LOS would have been 5±6 days instead of 6±4 days (P<0.001). Furthermore, the in-hospital death rate was higher (although not statistically significant) in patients who developed CI-AKI (4/64 [6%] versus 9/394 [2.5%]; P=0.076).
At baseline, NGAL (urine, serum, and normalized) and cystatin C were negatively correlated with eGFR ( Figure 1 ). Correlations between NGAL and sCr are reported in Figure  I in the Data Supplement. As represented in Figure 2 , values of uNGAL, sNGAL, uNGAL/uCr ratio, and cystatin C at the different time points began to diverge significantly between CI-AKI group and non CI-AKI group at 2 hours after CM injection (Figure 2 ). Cut-offs of uNGAL, sNGAL, uNGAL/ uCr ratio, and cystatin C for predicting CI-AKI are reported in the Table 2 and Table II in the Data Supplement. The best overall combination of sensitivity and specificity for uNGAL, sNGAL, and uNGAL/uCr ratio was observed at 6 hours after CM exposure and at 24 hours for cystatin C ( Table 3 . Consistent adjusted odds ratios (OR) were obtained for sNGAL ≥179 ng/mL and uNGAL ≥20 ng/mL, but not for uNGAL/uCr ratio ≥1.5.
Based on this result, sNGAL ≥179 ng/mL and uNGAL ≥20 ng/mL at 6 hours and cystatin C increase ≥10% at 24 hours were regarded the best thresholds for prediction of CI-AKI. In detail, the positive predictive value (PPV) and the negative predictive value (NPV) for CI-AKI of sNGAL, uNGAL, and cystatin C were 20% and 93%, 27% and 97%, and 27% and 91%, respectively. The characteristics of patients in the validation set were similar to those in the development set, besides the lower CM volume and the systematic use of the RenalGuard system (Table III in the Data Supplement). CI-AKI occurred in 29 of 253 (11.5%) patients in the validation set. uNGAL ≥20 ng/mL and sNGAL ≥179 ng/mL at 6 hours were observed in 139 (55%) and 130 (51%) patients, respectively. Although all the 29 patients who developed CI-AKI had high NGAL level at 6 hours, the overall PPV was low (uNGAL ≥20 ng/mL, 21%; sNGAL ≥179 ng/mL, 22%). On the contrary, the NPV was 100%, indeed no patients with sNGAL <179 ng/mL and uNGAL <20 ng/mL at 6 hours developed CI-AKI ( Figure 3 ). Cystatin C increase ≥10% at 24 hours showed a PPV of 21% and an NPV of 90%.
MAE and NGAL
In the development set, 1-year MAE occurred in 121 (26.4%) patients. In detail, 67 patients (14.6%) died, 17 (3.5%) patients needed dialysis (3 of whom eventually died), 11 (2.4%) had nonfatal myocardial infarction, 29 (6.3%) had myocardial revascularization, and 19 (4%) had sustained GFR reduction.
Death was cardiac in 67% of patients, noncardiac in 29.5% of patients, and unknown in 3.5% of patients. All the 19 patients who had sustained GFR reduction experienced also additional MAE at follow-up: indeed, 17 patients needed dialysis (3 of whom eventually died), 5 had nonfatal myocardial infarction, Table 4 . The MAE group had higher percentages of individuals with greater age, lower eGFR, higher contrast nephropathy risk score, and CI-AKI than did the event-free group.
Changes in uNGAL, sNGAL, and uNGAL/uCr ratio in relation to the occurrence of MAE are represented in the Figure 4 . sNGAL ≥179 ng/mL at 6 hours after CM exposure was the threshold predicting 1-year MAE ( Figure 4 and Table 5 ; Table IV proportional hazards models were used to provide corrected hazard ratio for each parameter, using the same confounding factors considered in the CI-AKI analysis ( Table 6 ). According to the defined cut-offs of kidney damage (ie, sNGAL ≥179 ng/mL at 6 hours) and functional change (ie, sCr ≥0.3 mg/ dL at 48 hours), MAE occurred in 27/198 (13.5%) patients in the group without kidney damage or functional change, in 57/193 (29.5%) patients in the group with kidney damage alone (unadjusted OR versus group 1 =2.83; 95% confidence interval 1.24-6.44; P=0.011), and in 37/67 (55%) patients in the group with functional change (unadjusted OR versus group 1 =6.64; 95% confidence interval 2.54-17.47; P<0.001; Figure 5 ). By logistic regression analysis, kidney damage alone and kidney functional change were independent predictors of 1-year MAE ( Table 7) . MAE at 1 year occurred in 31 of 141 (22%) patients in the validation set. sNGAL ≥179 ng/mL at 6 hours was observed in 75 (53%) patients. The overall PPV was 34.5%, and the NPV was 92.5%. Only 6 of the 68 (9%) patients in the group without kidney damage or functional change had 1-year MAE. On the contrary, 17/57 (30%) patients in the group with kidney damage alone (unadjusted OR versus group 1 =4.33; 95% confidence interval 1.92-9.75; P<0.001) and 8/16 (50%) patients in the group with functional change (unadjusted OR versus group 1 =7.03; 95% confidence interval 2.51-19.68; P<0.001) experienced 1-year MAE. 
Discussion
Biomarkers for CI-AKI Diagnosis
The results of the current study suggest that the following:
1. NGAL is a reliable marker for ruling out CI-AKI. This finding may allow physicians to discharge earlier ≈50% of patients at risk, thus avoiding unnecessary prolonged hospitalization with its associated practical and economic advantages. 2,3 2. High NGAL levels (uNGAL ≥20 mg/dL and sNGAL ≥179 mg/dL) at 6 hours occurred in >50% of patients. This confirms that, in high-risk patients, AKI after CM exposure occur more often than detected by sCr criteria. The observation that NGAL starts to increase within 2 hours after CM administration is consistent with the experimental finding that the cytotoxic effects of the CM occur within minutes to hours from exposure. 23 3. uNGAL ≥20 ng/mL and sNGAL ≥179 ng/mL at 6 hours after CM exposure anticipate a significant sCr increase in only 20% of cases. 12, 24 This low PPV limits the clinical relevance of NGAL assessment in the setting of CI-AKI. Several reasons have been proposed to explain this inconsistency of NGAL performance in AKI: (1) heterogeneity in baseline renal function, 25 (2) different definition and severity of AKI, [25] [26] [27] (3) different clinical settings, 9 and (4) the current diagnosis of AKI, which relies on the assessment of sCr, rather than a marker of AKI. 13,28,29 4. NGAL performance is superior to that of serum cystatin C in ruling out CI-AKI. We previously observed that a serum cystatin C increase <10% at 24 hours is a reliable marker for ruling out CI-AKI. 17 Although confirmed in the present study, the clinical performance of this serum cystatin C threshold was inferior to that of NGAL. Both biomarkers, however, showed a similar low PPV. 
NGAL and Prognosis
High (≥179 ng/mL) sNGAL at 6 hours after CM exposure is an independent predictor of unfavorable outcome. This supports the concept that AKI likely exists when NGAL is increased, independently of any increase in sCr. 9, 13 Therefore, NGAL and sCr reflect distinct pathophysiological events. 3 Haase et al 13 and Nickolas et al 9 demonstrated that, in the absence of a diagnostic increase in sCr, NGAL-positive patients might still have AKI and carry a worse prognosis than NGAL-negative patients. Increased NGAL was also found highly predictive of clinical outcome, including nephrology consultation, renal replacement therapy, and admission to the intensive care unit. 28 In the current study, sNGAL but not uNGAL resulted as an independent predictor of 1-year MAE. A recent systematic review and meta-analysis support that the diagnostic accuracy of plasma NGAL/sNGAL is similar to that of uNGAL. 12 However, uNGAL is more representative of the renal pool, whereas sNGAL represents the systemic pool. 30 In fact, uNGAL is mainly produced by the distal nephron after injury and is immediately secreted into the urine. 24 In contrast, although sNGAL probably arises predominantly from injured thick ascending tubules and collecting ducts, it is a product of multiple sources and might be a good biomarker of inflammation. 13, 24 Indeed, sNGAL may reveal the effect of toxins that injure multiple organs other than kidney. 24 Furthermore, sNGAL measurements may be affected by several coexisting variables, such as chronic kidney disease, hypertension, systemic infections, inflammatory conditions, anemia, and hypoxia.
Study Limitations
The present study refers to a high-risk population with a mean eGFR of ≈30 mL/min per 1.73 m 2 ; therefore, the results should not be extended for patients with normal or †sNGAL ≥179 ng/mL at 6 h, and sCr increases <0.3 mg/dL at 48 h. ‡sCr increases ≥0.3 mg/dL at 48 h irrespective to the sNGAL at 6 h. Patients with functional change alone and those with both kidney damage and functional change were combined because of the limited number (n=8) in the group with functional change alone. NGAL and Contrast-Induced Acute Kidney Injury moderately depressed kidney function. Moreover, patients who experienced MAE at follow-up had higher percentages CI-AKI, greater age, lower eGFR, and higher contrast nephropathy risk score. Therefore, additional studies are necessary to (1) confirm these findings in a larger testing population and (2) assess whether the early diagnosis of CI-AKI through NGAL dosage is cost-effective and associated with better clinical outcome.
Conclusions
Low NGAL (uNGAL <20 mg/dL and sNGAL <179 mg/dL) at 6 hours after CM exposure is a reliable marker for ruling out CI-AKI. On the contrary, high NGAL (uNGAL ≥20 mg/dL and sNGAL ≥179 mg/dL) at 6 hours is a poor predictor of CI-AKI. Furthermore, sNGAL ≥179 mg/dL at 6 hours predicts 1-year MAE.
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